抗凝类型与心源性卒中早期复发:IAC研究
本研究基于美国8个综合卒中中心登记数据,纳入急性缺血性卒中合并房颤患者,比较直接口服抗凝药(DOAC)与华法林、桥接抗凝与不桥接对90天复发性缺血事件及迟发性症状性颅内出血的影响。结果显示桥接治疗增加迟发性症状性颅内出血风险,DOAC降低复发性缺血事件风险。
要点
- 桥接抗凝较不桥接增加迟发性症状性颅内出血风险(HR 2.74)。
- DOAC较华法林降低复发性缺血事件风险(HR 0.51)。
- DOAC与华法林在迟发性症状性颅内出血风险上无显著差异。
核心结论
- 缺血性卒中合并房颤患者可能受益于起始DOAC治疗且不进行桥接抗凝。
研究设计与样本
- IAC研究汇总美国8个综合卒中中心卒中登记数据,纳入连续急性缺血性卒中合并房颤患者。
- 桥接与不桥接分析纳入1289例,DOAC与华法林分析纳入1251例。
主要发现
- 桥接治疗较不桥接与迟发性症状性颅内出血高风险相关(HR 2.74,95%CI 1.01-7.42)。
- 桥接治疗与不桥接的复发性缺血事件发生率相似(HR 1.23,95%CI 0.63-2.40)。
- DOAC较华法林与复发性缺血事件低风险相关(HR 0.51,95%CI 0.29-0.87)。
- DOAC与华法林的迟发性症状性颅内出血风险无显著差异(HR 0.57,95%CI 0.22-1.48)。
临床怎么用
- 对于急性缺血性卒中合并房颤患者,可考虑起始DOAC治疗且避免桥接抗凝。
局限性
- 研究结果需谨慎解读,有待大型前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In patients with acute ischemic stroke and atrial fibrillation, treatment with low molecular weight heparin increases early hemorrhagic risk without reducing early recurrence, and there is limited data comparing warfarin to direct oral anticoagulant (DOAC) therapy. We aim to compare the effects of the treatments above on the risk of 90-day recurrent ischemic events and delayed symptomatic intracranial hemorrhage. METHODS: We included consecutive patients with acute ischemic stroke and atrial fibrillation from the IAC (Initiation of Anticoagulation after Cardioembolic) stroke study pooling data from stroke registries of 8 comprehensive stroke centers across the United States. We compared recurrent ischemic events and delayed symptomatic intracranial hemorrhage between each of the following groups in separate Cox-regression analyses: (1) DOAC versus warfarin and (2) bridging with heparin/low molecular weight heparin versus no bridging, adjusting for pertinent confounders to test these associations. RESULTS: We identified 1289 patients who met the bridging versus no bridging analysis inclusion criteria and 1251 patients who met the DOAC versus warfarin analysis inclusion criteria. In adjusted Cox-regression models, bridging (versus no bridging) treatment was associated with a high risk of delayed symptomatic intracranial hemorrhage (hazard ratio, 2.74 [95% CI, 1.01-7.42]) but a similar rate of recurrent ischemic events (hazard ratio, 1.23 [95% CI, 0.63-2.40]). Furthermore, DOAC (versus warfarin) treatment was associated with a lower risk of recurrent ischemic events (hazard ratio, 0.51 [95% CI, 0.29-0.87]) but not delayed symptomatic intracranial hemorrhage (hazard ratio, 0.57 [95% CI, 0.22-1.48]). CONCLUSIONS: Our study suggests that patients with ischemic stroke and atrial fibrillation would benefit from the initiation of a DOAC without bridging therapy. Due to our study limitations, these findings should be interpreted with caution pending confirmation from large prospective studies.
引用
- Yaghi S, Mistry E, Liberman AL, et al. Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. Stroke. 2020. PMID: 32757753. doi:10.1161/STROKEAHA.120.028867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。